Tetra Bio Pharma Inc - CEO, Guy Chamberland
CEO, Guy Chamberland
Source: Youtube (Tetra Bio-Pharama)
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cannabinoid-drug developer, Tetra Bio-Pharma (TSXV:TBP) has received approval from Health Canada to recommence a veterinary clinical study
  • The study will investigate how effectively the company’s ophthalmic drug treats indolent corneal ulcers in companion animals and pets
  • The study had to halt in April, when new COVID-19 regulations stopped participants from bringing their pets to the clinic
  • Health Canada’s Veterinary Drugs Directorate has renewed the trial, with treatment beginning as soon as clinics reopen to the public
  • Tetra Bio-Pharma (TBP) is up 1.52 per cent, with shares trading for C$0.34 and a $82.1 million market cap

Cannabinoid-drug developer, Tetra Bio-Pharma (TSXV:TBP) has received approval from Health Canada to recommence a veterinary clinical study.

The study will investigate the efficacy of the company’s ophthalmic drug in the treatment of indolent corneal ulcers. The trial is focusing on companion animals and pets.

The trial previously had to halt, due to concerns surround the COVID-19 pandemic. New restrictions hindered participants from bringing their pets to the treatment centre. As a result, enrolment was difficult, and the company postponed the study in April.

However, with new case numbers in Canada beginning to slow, Health Canada’s Veterinary Drugs Directorate has renewed the trial. The renewal has extended the maximum length of the trial by another year.

By the time the study had to halt, half of the participants had already completed the trial’s treatment and follow-up phase. None had shown any adverse side effects from the drug.

The remaining participant will start the trial as soon as veterinary clinics reopen to the public.

Tetra Bio-Pharma’s CRO and CEO, Guy Chamberland, was pleased the trial can now safely continue.

“As a health care corporation, Tetra fully supports the measures taken by governments to protect its citizens.

“These measures had only a minor impact on the ophthalmic operations compared to the significant public health benefit. We are glad that the participants and support staff involved in the trial are healthy and safe and that we can now initiate re-activation of the trial,” he said.

Tetra Bio-Pharma (TBP) is up 1.52 per cent, with shares trading for C$0.34 at 11:52am EDT. 

More From The Market Herald

" Oncolytics Biotech (TSX:ONC) advances Chinese cancer trial

Oncolytics Biotech (ONC) partner, Adlai Nortye, reported results from a clinical evaluation of pelareorep-paclitaxel combination therapy for advanced breast cancer.

" MCI Onehealth (TSX:DRDR) clinical data insights pipeline gains momentum

MCI Onehealth (DRDR) is evolving its tech and clinical data insights through revenue deals and relationships with businesses in health and life-sciences.

" BriaCell (TSX:BCT) releases positive clinical and quality of life data in advanced metastatic breast cancer study

BriaCell Therapeutics (BCT) presented positive safety/tolerability and efficacy data from its lead product candidate, Bria-IMT.

" Sirona Biochem (TSXV:SBM) begins clinical trial for anti-aging compound TFC-1326

Sirona Biochem Corp. (SBM) has begun the clinical trial for its novel anti-aging compound TFC-1326.